Segall Bryant & Hamill LLC Decreases Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Segall Bryant & Hamill LLC trimmed its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 2.2% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,384,439 shares of the medical instruments supplier's stock after selling 30,717 shares during the period. Segall Bryant & Hamill LLC owned approximately 3.41% of AngioDynamics worth $13,000,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ANGO. Quinn Opportunity Partners LLC acquired a new stake in AngioDynamics in the 4th quarter valued at $92,000. ProShare Advisors LLC bought a new stake in shares of AngioDynamics during the fourth quarter valued at about $100,000. Graham Capital Management L.P. purchased a new position in shares of AngioDynamics during the fourth quarter worth about $106,000. OneDigital Investment Advisors LLC grew its holdings in shares of AngioDynamics by 14.0% during the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock worth $121,000 after buying an additional 2,333 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ANGO has been the subject of a number of recent analyst reports. Lake Street Capital initiated coverage on AngioDynamics in a report on Wednesday. They set a "buy" rating and a $24.00 target price for the company. Canaccord Genuity Group set a $17.00 target price on AngioDynamics and gave the company a "buy" rating in a report on Wednesday. Finally, HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a report on Wednesday.

AngioDynamics Price Performance

Shares of AngioDynamics stock traded down $0.05 during trading on Friday, hitting $8.69. 719,749 shares of the company's stock traded hands, compared to its average volume of 589,754. AngioDynamics, Inc. has a 1 year low of $5.83 and a 1 year high of $13.50. The stock has a market capitalization of $352.90 million, a P/E ratio of -10.47 and a beta of 0.60. The business has a 50-day simple moving average of $9.86 and a 200-day simple moving average of $10.08.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The business had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. During the same period last year, the firm posted ($0.06) earnings per share. The business's revenue for the quarter was up 13.0% on a year-over-year basis. On average, equities analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.